Imatinib mesylate (IM) is a selective and specific ABL-tyrosine kinase inhibitor that shows outstanding therapeutic benefits for patients with CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.